Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AMGT-0230
- Development stage
- Preclinical
- Lead developer
- Amalgent Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**AMGT-0230** is a preclinical Amalgent Therapeutics pain-treatment candidate publicly described as a next-generation extended-release therapy for moderate-to-severe pain. The precise active ingredient, molecular structure, pharmacologic target, and mechanism of action have not been publicly disclosed in sources located for this exact code. ([synapse.patsnap.com](https://synapse.patsnap.com/drug/e4475776440e497fbdb6278444f73088))
02
Targets
DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)MOR (Mu opioid receptor)
Beyond the preview
Go deeper on AMGT-0230.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AMGT-0230.